Oncology and Hematology - Prova Education

Episodes 17-32 of 62

Optimal Sequencing of ADCs in Endocrine Refractory HR+/HER2- Metastatic Breast Cancer
Optimal Sequencing of ADCs in Endocrine Refractory HR+/HER2- Metastatic Breast Cancer
CME/CE
Optimal Sequencing of ADCs in Endocrine Refractory HR+/HER2- Metastatic Breast Cancer
0.50 credits
- Javier Cortes, MD, PhD
- Komal Jhaveri, MD, FACP
0.50 credits
GPRC5D-Targeted Bispecifics in Relapsed/Refractory Multiple Myeloma: Practical Expert Consensus on a New Target with Unique Adverse Events
GPRC5D-Targeted Bispecifics in Relapsed/Refractory Multiple Myeloma: Practical Expert Consensus on a New Target with Unique Adverse Events
CME/CE
GPRC5D-Targeted Bispecifics in Relapsed/Refractory Multiple Myeloma: Practical Expert Consensus on a New Target with Unique Adverse Events
0.25 credits
- Jeffrey V. Matous, MD
0.25 credits
GPRC5D-Targeted Bispecifics in Relapsed/Refractory Multiple Myeloma: Practical Expert Consensus on a New Target with Unique Adverse Events
GPRC5D-Targeted Bispecifics in Relapsed/Refractory Multiple Myeloma: Practical Expert Consensus on a New Target with Unique Adverse Events
CME/CE
GPRC5D-Targeted Bispecifics in Relapsed/Refractory Multiple Myeloma: Practical Expert Consensus on a New Target with Unique Adverse Events
0.50 credits
- Jeffrey V. Matous, MD
- Donna Catamero, NP
- Ajai Chari, MD
0.50 credits
Applying SDM to Personalize Treatment Discussions on Recurrence Risk Reduction in Patients with Early-Stage Melanoma
Applying SDM to Personalize Treatment Discussions on Recurrence Risk Reduction in Patients with Early-Stage Melanoma
CME/CE
Applying SDM to Personalize Treatment Discussions on Recurrence Risk Reduction in Patients with Early-Stage Melanoma
0.25 credits
- Meghan Mooradian, MD
0.25 credits
Hematologic Adverse Events With ADCs in Breast Cancer: Optimal Management Strategies
Hematologic Adverse Events With ADCs in Breast Cancer: Optimal Management Strategies
MinuteCE®
Hematologic Adverse Events With ADCs in Breast Cancer: Optimal Management Strategies
1.00 program credit
- Nadia Harbeck, MD, PhD
1.00 program credit
Managing ADC-Related Pulmonary and Cardiac AEs in NSCLC
Managing ADC-Related Pulmonary and Cardiac AEs in NSCLC
MinuteCE®
Managing ADC-Related Pulmonary and Cardiac AEs in NSCLC
1.00 program credit
- Egbert Smit, MD
1.00 program credit
Managing Pulmonary and Cardiac Adverse Events Related to ADC Therapy in Breast Cancer
Managing Pulmonary and Cardiac Adverse Events Related to ADC Therapy in Breast Cancer
MinuteCE®
Managing Pulmonary and Cardiac Adverse Events Related to ADC Therapy in Breast Cancer
1.00 program credit
- Nadia Harbeck, MD, PhD
1.00 program credit
MinuteCE®
Mastering the AEs of ADCs to Unlock Their Full Potential in Breast, Lung, and Gynecologic Cancer
1.00 credit 10 episodes
- Nadia Harbeck, MD, PhD
- Egbert Smit, MD
- Susana Campos, MD, MPH
1.00 credit 10 episodes
Optimal Management of ADC-Related Gastrointestinal AEs in NSCLC
Optimal Management of ADC-Related Gastrointestinal AEs in NSCLC
MinuteCE®
Optimal Management of ADC-Related Gastrointestinal AEs in NSCLC
1.00 program credit
- Egbert Smit, MD
1.00 program credit
ADCs in Gynecologic Cancers: Managing Pulmonary and Cardiac TEAEs
ADCs in Gynecologic Cancers: Managing Pulmonary and Cardiac TEAEs
MinuteCE®
ADCs in Gynecologic Cancers: Managing Pulmonary and Cardiac TEAEs
1.00 program credit
- Susana Campos, MD, MPH
1.00 program credit
Gastrointestinal and Hematologic TEAEs Related to ADC Therapy in Gynecologic Cancers
Gastrointestinal and Hematologic TEAEs Related to ADC Therapy in Gynecologic Cancers
MinuteCE®
Gastrointestinal and Hematologic TEAEs Related to ADC Therapy in Gynecologic Cancers
1.00 program credit
- Susana Campos, MD, MPH
1.00 program credit
ADCs on the Horizon for Breast Cancer: Managing Treatment-Emergent Toxicities
ADCs on the Horizon for Breast Cancer: Managing Treatment-Emergent Toxicities
MinuteCE®
ADCs on the Horizon for Breast Cancer: Managing Treatment-Emergent Toxicities
1.00 program credit
- Nadia Harbeck, MD, PhD
1.00 program credit
Emerging ADC Therapies for NSCLC: Anticipating AEs Reported in Clinical Trials
Emerging ADC Therapies for NSCLC: Anticipating AEs Reported in Clinical Trials
MinuteCE®
Emerging ADC Therapies for NSCLC: Anticipating AEs Reported in Clinical Trials
1.00 program credit
- Egbert Smit, MD
1.00 program credit
ADC-Related Hematologic Adverse Events
ADC-Related Hematologic Adverse Events
MinuteCE®
ADC-Related Hematologic Adverse Events
1.00 program credit
- Egbert Smit, MD
1.00 program credit
Risk Reduction and Management Protocols for Gastrointestinal Adverse Events With ADC Therapy in Breast Cancer
Risk Reduction and Management Protocols for Gastrointestinal Adverse Events With ADC Therapy in Breast Cancer
MinuteCE®
Risk Reduction and Management Protocols for Gastrointestinal Adverse Events With ADC Therapy in Breast Cancer
1.00 program credit
- Nadia Harbeck, MD, PhD
1.00 program credit
Cracking the CRS Code in Myeloma: Insights from a Comprehensive Case Review
Cracking the CRS Code in Myeloma: Insights from a Comprehensive Case Review
CME/CE
Cracking the CRS Code in Myeloma: Insights from a Comprehensive Case Review
0.25 credits
- Caitlin Costello, MD
- Sagar Lonial, MD, FACP
0.25 credits

2/4